Patents Issued in March 26, 2019
  • Patent number: 10239911
    Abstract: A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: March 26, 2019
    Assignee: Atea Pharmaceuticals, Inc.
    Inventors: Jean-Pierre Sommadossi, Adel Moussa
  • Patent number: 10239912
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: March 26, 2019
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Laurent Pierre Paul Debien, Juan Carlos Jaen, Jaroslaw Kalisiak, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Dillon Harding Miles, Eric Newcomb, Jay Patrick Powers, Brandon Reid Rosen, Ehesan Ul Sharif
  • Patent number: 10239913
    Abstract: Compounds and methods of synthesizing oxysterols are provided. The compounds and methods provided allow the oxysterol to be safely produced at a high yield. The compounds and methods provided can produce the oxysterol in a stereoselective manner. The method comprises reacting a diol with borane and hydrogen peroxide to form the oxysterol or a pharmaceutically acceptable salt, hydrate or solvate thereof.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: March 26, 2019
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Roger E. Harrington, Jerbrena C. Jacobs, Damodaragounder Gopal, Ke-Qing Ling, Marco Burello
  • Patent number: 10239914
    Abstract: An improvement of deprotection in solid phase peptide synthesis is disclosed. The method includes the steps of adding the deprotection composition in high concentration and small volume to the mixture of the coupling solution, the growing peptide chain, and any excess activated amino acid from the preceding coupling cycle; and without any draining step between the coupling step of the previous cycle and the addition of the deprotection composition for the successive cycle; and with the coupling solution at a temperature of at least 30° C.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: March 26, 2019
    Assignee: CEM Corporation
    Inventor: Jonathan M. Collins
  • Patent number: 10239915
    Abstract: This invention is intended to produce a novel functional material through solubilization and molecular weight reduction of a water-insoluble polymeric compound, such as a water-insoluble protein or water-insoluble polysaccharide, in a simple and efficient manner.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: March 26, 2019
    Assignees: JELLYFISH RESEARCH LABORATORIES, INC., MARUWA OIL & FAT CO., LTD.
    Inventors: Satoshi Shinohara, Takayuki Baba, Koji Kihira
  • Patent number: 10239916
    Abstract: The invention provides a method for the creation of peptide antigens comprising epitopes with at least a first modification comprising a shortened or lengthened amino acid side chain. By extension or shortening of the side chain with CH3/CH2 groups, for example, made by computer assisted modeling of the tumor antigen (peptide) bound in the MHC-I-groove, immunogenicity can be improved with minimal modification of adjacent tertiary structure, thereby avoiding cross-reactivity. Provided by the invention are methods of creating such antigens, as well as methods for therapeutic or prophylactic treatment of various conditions comprising administration of the antigens.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: March 26, 2019
    Assignees: Board of Regents, The University of Texas Systems, Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Constantin G. Ioannides, Martin L. Campbell, Catherine A. O'Brian, George E. Peoples
  • Patent number: 10239917
    Abstract: A novel method for human minor histocompatibility antigen (MiHA) discovery, novel MiHAs identified using this method, as well as uses of the novel MiHAs, are described. One of the features of the novel method is the inclusion of personalized translated transcriptome and/or exome in the database used for peptide identification by mass spectroscopy (MS). Candidate MiHAs are identified by comparing the personalized transcriptome and/or exome to a reference genome and/or to the transcriptome and/or exome of an HLA-matched subject.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: March 26, 2019
    Assignee: UNIVERSITÉ DE MONTRÉAL
    Inventors: Claude Perreault, Pierre Thibault, Sébastien Lemieux, Diana Paola Granados, Sriranganadane Dev, Mohamed Tariq Daouda, Olivier Caron-Lizotte
  • Patent number: 10239918
    Abstract: Provided herein are biofilm inhibitors obtained from marine microbial derived natural product extracts from Streptomyces gandocaensis, resulting in biofilm inhibitors, cahuitamycins. Also provided are mutant S. gandocaensis, methods of inhibiting biofilm formation, methods of producing, or increasing the production of, cahuitamycins, methods for synthesizing cahuitamycins, and methods of purifying cahuitamycins.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: March 26, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: David H. Sherman, Fengan Yu, Chuanwu Xi, Jianfeng Wu, Pamela J. Schultz, Ashootosh Tripathi, Sung Ryeol Park
  • Patent number: 10239919
    Abstract: Disclosed herein is a selective delivery molecule comprising: (a) an acidic sequence (portion A) which is effective to inhibit or prevent the uptake into cells or tissue retention, (b) a molecular transport or retention sequence (portion B), and (c) a linker between portion A and portion B, and (d) at least one cargo moiety.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: March 26, 2019
    Assignee: AVELAS BIOSCIENCES, INC.
    Inventors: Jesus Gonzalez, Junjie Liu
  • Patent number: 10239920
    Abstract: The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The invention further discloses methods for treating cancer and diagnosing cancer.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: March 26, 2019
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Ananda Chakrabarty, Tapas Das Gupta, Tohru Yamada, Arsenio Fialho
  • Patent number: 10239921
    Abstract: Compositions and methods for controlling plant pests are disclosed. In particular, novel engineered hybrid insecticidal proteins (eHIPs) having toxicity to at least corn rootworm are provided. By fusing unique combinations of complete or partial variable regions and conserved blocks of at least two different Bacillus thuringiensis (Bt) Cry proteins or a modified Cry proteins an eHIP having activity against corn rootworm is designed. Nucleic acid molecules encoding the novel eHIPs are also provided. Methods of making the eHIPs and methods of using the eHIPs and nucleic acids encoding the eHIPs of the invention, for example in transgenic plants to confer protection from insect damage are also disclosed.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: March 26, 2019
    Assignee: Syngenta Participations AG
    Inventors: Hope Hart, Jeng Shong Chen, Cheryl M. Defontes, Frederick Walters
  • Patent number: 10239922
    Abstract: The present disclosure pertains to methods of producing recombinant peptides that contain between 10 and 200 amino acid residues using novel carrier proteins derived from superfolder green fluorescent protein and its mutants.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: March 26, 2019
    Assignee: Suzhou Kunpeng Biotech Co., Ltd.
    Inventors: Wenshe Liu, Wei Wan
  • Patent number: 10239923
    Abstract: Peptides specifically binding amyloid beta and to methods of treating and diagnosing Alzheimer's dementia using such peptides are provided.
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: March 26, 2019
    Assignee: FORSCHUNGSZENTRUM JUELICH GMBH
    Inventors: Dieter Willbold, Stephan Rudolph, Janine Kutzsche, Susanne Aileen Funke
  • Patent number: 10239924
    Abstract: A peptide having eight amino acid sequences derived from cancer-associated gene (CAGE) is described which retains anticancer activity and activity to promote anticancer drug sensitivity of anticancer drug resistant cancer cells. Specifically, a peptide which has an amino acid sequence of SEQ ID NO: 1 (AQTGTGKT) and thus binds to the CAGE protein is disclosed, which inhibits an inter-linkage between CAGE and GSK3?, thus exhibiting anticancer activity and activity to promote anticancer drug sensitivity of anticancer drug resistant cancer cells. A pharmaceutical composition is also disclosed containing the peptide with the amino acid sequence of SEQ ID NO: 1 (AQTGTGKT), for anticancer use or anticancer drug aiding.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: March 26, 2019
    Assignee: L-BASE CO., LTD.
    Inventors: Doo Il Jeoung, Young Mi Kim, Hyun A Kim
  • Patent number: 10239925
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: March 26, 2019
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Helen Hoerzer, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10239926
    Abstract: As described herein, the present invention features compositions comprising an HGF/IgG complex and methods of using such compositions to reduce ischemic reperfusion injury.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: March 26, 2019
    Assignee: The University of Vermont and State Agriculture College
    Inventor: Jeffrey Spees
  • Patent number: 10239927
    Abstract: The present invention provides new protease resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: March 26, 2019
    Assignee: Novartis AG
    Inventors: Kristen Johnson, Jian Shi
  • Patent number: 10239928
    Abstract: The present invention provides a plant expressing a target protein, a method of preparing the same and a method of preparing a composition for oral administration of a biopharmaceutical using the same. A target protein expression system using plant cells according to the present invention solves conventional problems in plant cell culture, provides a method of producing a large quantity of target proteins including a biopharmaceutical protein and allowing a target protein to have a resistance to a protease present in a digestive organ, and therefore is very effective to enable commercialization of plant-derived biopharmaceuticals.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: March 26, 2019
    Assignee: POSTECH ACADEMY-INDUSTRY FOUNDATION
    Inventors: Inhwan Hwang, Hyang Ju Kang, Eun Ju Sohn, Yong Jik Lee, Per-Olof Berggren, Yun Joo Yoo, Jae Yoon Kim
  • Patent number: 10239929
    Abstract: Provided herein are methods for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. A peptide selected from sequences SEQ ID NO: 12, SEQ ID NO: 15 and SEQ ID NO: 17 are administered.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: March 26, 2019
    Assignee: KeyBioscience AG
    Inventors: Nozer M. Mehta, William Stern, Amy M. Sturmer, Morten Asser Karsdal, Kim Henriksen
  • Patent number: 10239930
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: March 26, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10239931
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: March 26, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Anita Wiebe, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10239932
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: March 26, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10239933
    Abstract: Factor V peptides and methods of use thereof are disclosed.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: March 26, 2019
    Assignee: The Children's Hospital of Philadelphia
    Inventors: Rodney M. Camire, Matthew W. Bunce, Mettine H. A. Bos
  • Patent number: 10239934
    Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: March 26, 2019
    Assignees: Theraclone Sciences, Inc., International AIDS Vaccine Initiative, The Scripps Research Institute
    Inventors: Po-Ying Chan-Hui, Steven Frey, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Sanjay K. Phogat, Dennis R. Burton, Laura Marjorie Walker, Pascal Raymond Georges Poignard, Wayne Koff, Melissa Danielle De Jean De St. Marcel Simek-Lemos, Stephen Kaminsky
  • Patent number: 10239935
    Abstract: The present invention provides novel anti-HIV antibodies with improved therapeutic properties, related pharmaceutical compositions, and methods of use thereof.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: March 26, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Mini Balakrishnan, Brian A. Carr, John Corbin, Craig S. Pace, Nathan D. Thomsen, Xue Zhang
  • Patent number: 10239936
    Abstract: Disclosed are compositions and methods related to variable lymphocyte receptors (VLRs). More particularly, disclosed are a variety of antigen specific polypeptides, including soluble, monoclonal, and multivalent forms, as well as methods of using the polypeptides, antibodies that bind the antigen specific polypeptides, and nucleic acids, vectors and expression systems that encode the polypeptides. Antigen specific polypeptides that selectively bind pathogens, like anthrax, and carbohydrates, like blood group determinants, are specifically disclosed.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: March 26, 2019
    Assignee: The UAB Research Foundation
    Inventors: Max D. Cooper, Brantley R. Herrin, Matthew N. Alder
  • Patent number: 10239937
    Abstract: Methods for treating subjects having complement-mediated hemolytic disorders, such as paroxysmal nocturnal hemoglobinuria (PNH) and other hemolytic anemias, the method comprising administering an effective amount of a composition that inhibits the activity of the complement alternative pathway.
    Type: Grant
    Filed: November 5, 2010
    Date of Patent: March 26, 2019
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: V. Michael Holers, Antonio M. Risitano
  • Patent number: 10239938
    Abstract: The present invention concerns compositions and methods of use of T-cell redirecting complexes, with at least one binding site for a T-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a DNL™ complex. More preferably, the complex comprises a bispecific antibody (bsAb). Most preferably, the bsAb is an anti-CD3×anti-CD19 bispecific antibody, although antibodies against other T-cell antigens and/or disease-associated antigens may be used. The complex is capable of targeting effector T cells to induce T-cell-mediated cytotoxicity of cells associated with a disease, such as cancer, autoimmune disease or infectious disease. The cytotoxic immune response is enhanced by co-administration of interferon-based agents that comprise interferon-?, interferon-?, interferon-?1, interferon-?2 or interferon-?3.
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: March 26, 2019
    Assignee: IBC Pharmaceuticals, Inc.
    Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi, Diane Rossi, Hans J. Hansen
  • Patent number: 10239939
    Abstract: Specific binding members that bind the ED-A isoform of fibronectin for use in methods of treatment, diagnosis, detection and/or imaging of inflammatory bowel disease (IBD), and/or for use in delivery to the IBD tissue of a molecule conjugated to the specific binding member. The specific binding member may, for example, be conjugated to an immunosupressive or anti-inflammatory molecule, such as interleukin-10.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: March 26, 2019
    Assignee: PHILOGEN S.P.A.
    Inventors: Giovanni Neri, Kathrin Schwager, Melanie C. Ruzek, Denise M. O'hara, Jianqing Chen
  • Patent number: 10239940
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: March 26, 2019
    Assignee: ACCELERON PHARMA INC.
    Inventors: John Knopf, Jasbir Seehra
  • Patent number: 10239941
    Abstract: The present application relates to antibodies that specifically bind to hepcidin and methods of using the antibodies. Another aspect relates to antibodies which bind hepcidin and regulate iron homeostasis. Another aspect relates to the use of humanized antibodies which bind hepcidin for the treatment of a disease or condition associated with hepcidin.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: March 26, 2019
    Assignee: Intrinsic Lifesciences LLC
    Inventors: Mark Westerman, Vaughn Ostland, Huiling Han, Patrick Gutschow, Keith Westerman, Gordana Olbina
  • Patent number: 10239942
    Abstract: Antibodies that bind to programmed cell death protein 1 (PD-1), compositions comprising such antibodies, and methods of making and using such antibodies are disclosed.
    Type: Grant
    Filed: December 19, 2015
    Date of Patent: March 26, 2019
    Assignee: PD-1 Acquisition Group, LLC
    Inventors: Najmia Amirina, Hareesh Chamarthi, Maria Isabel Chiu, Daniel Doty, Bin Feng, Aleksander Jonca, Thomas McQuade, Anhco Nguyen, Sheila Ranganath, Hans Albert Felix Scheuplein, Vikki A. Spaulding, Lei Wang, Jennifer Watkins-Yoon, Sri Sahitya Vadde
  • Patent number: 10239943
    Abstract: Provided herein are methods and uses involving antibodies that specifically bind to a KIT receptor tyrosine kinase for managing, treating, or preventing an eosinophil or mast cell related disorder and/or one or more symptoms thereof, for example a mast cell related disorder of the nervous system, e.g., central nervous system, for example neuromyelitis optica (NMO), neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS), and neurofibromatosis (NF).
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: March 26, 2019
    Assignee: Celldex Therapeutics, Inc.
    Inventors: Theresa Marie LaVallee, Gerald McMahon
  • Patent number: 10239944
    Abstract: The present invention relates to compositions and methods of engineered IgG Fc constructs, wherein said Fc constructs include one or more Fc domains.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: March 26, 2019
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Carlos J. Bosques, James S. Huston, Jonathan C. Lansing, Leona E. Ling, James Meador, III, Daniel Ortiz, Laura Rutitzky
  • Patent number: 10239945
    Abstract: Provided are anti-CD47 monoclonal antibodies (anti-CD47 mAbs) with distinct functional profiles as described herein, methods to generate anti-CD47 mAbs, and to methods of using these anti-CD47 mAbs as therapeutics for the prevention and treatment of solid and hematological cancers, ischemia-reperfusion injury, cardiovascular diseases, autoimmune diseases, inflammatory diseases or as diagnostics for determining the level of CD47 in tissue samples.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: March 26, 2019
    Assignee: Arch Oncology, Inc.
    Inventors: Pamela T. Manning, Robyn Puro, Juan C. Almagro, Robert W. Karr
  • Patent number: 10239946
    Abstract: The invention relates to a cell line expressing the gamma chain of the Fc?RI receptor and human CD303 antigen, characterized in that said cell line is transfected in a stable manner by an expression vector comprising a nucleic acid molecule coding for human CD303 antigen and having strong expression of human CD303 on the surface thereof, e.g. at least 10000 molecules of human CD303 per cell, as well as a vector or vector kit that can be used to co-express the gamma chain of the Fc?RI receptor and human CD303 antigen, and different uses of the cell line of the invention.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: March 26, 2019
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Nathalie Fournier, Christophe De Romeuf
  • Patent number: 10239947
    Abstract: The invention provides anti-CLL-1 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: March 26, 2019
    Assignee: Genentech, Inc.
    Inventors: Bing Zheng, Andrew Polson, Cecilia Chiu, Wei-Ching Liang, Yan Wu
  • Patent number: 10239948
    Abstract: The present invention relates to a method to engineer immune cell for immunotherapy. In particular said immune cells are engineered with chimeric antigen receptors, which be activated by the combination of hypoxia and ligand extracellular binding as input signals. The invention also relates to new designed chimeric antigen receptors which are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties and the hypoxia condition. The present invention also relates to cells obtained by the present method, in particular T-cells, comprising said chimeric antigen receptors for use in cancer treatments.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: March 26, 2019
    Assignee: CELLECTIS
    Inventors: Alexandre Juillerat, Claudia Bertonati, Julien Valton, Philippe Duchateau, Laurent Poirot
  • Patent number: 10239949
    Abstract: The present disclosure relates to protein molecules that specifically bind to 5T4 and/or 4-1BB. The molecules may have at least one humanized 5T4-binding or 4-1BB-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to 5T4 or 4-1BB may have a second binding domain that binds to another target. The molecules may bind both 5T4-expressing cells and a cell-surface molecule expressed by an effector cell to enhance effector cell activation, proliferation, survival and/or effector-cell mediated cytotoxicity. The disclosure also provides pharmaceutical compositions comprising the 5T4-binding or 4-1BB-binding polypeptide or protein molecules, nucleic acid molecules encoding these polypeptides and methods of making and using these molecules.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: March 26, 2019
    Assignees: Aptevo Research and Development, LLC, Alligator Bioscience AB
    Inventors: David Bienvenue, Gabriela Hernandez-Hoyos, Lynda Misher, Danielle Mitchell, Peter Ellmark, Anna Sall, Christina Furebring, Laura von Schantz, Sara Fritzell, Laura Varas
  • Patent number: 10239950
    Abstract: The present invention provides: an antibody exhibiting specificity for MUC1, the antibody having a glycan structure expressed at high levels in cancer cells; a method for manufacturing this antibody; and a novel means and method for the diagnosis and prevention and/or treatment of cancer using this antibody. The present invention is a monoclonal antibody to human MUC1, wherein the antibody specifically recognizes a glycopeptide having a human MUC1 tandem unit and furthermore having an O-linked glycan core (0(Tn)) in any one of the threonine and serine in the amino acid sequence of this human MUC1 tandem unit. A method for detecting MUC1 in a human body-fluid sample. A kit including this monoclonal antibody. A pharmacological composition for the prevention and/or treatment of a malignant tumor, the pharmacological composition containing this monoclonal antibody as an active ingredient.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: March 26, 2019
    Assignee: MEDICINAL CHEMISTRY PHARMACEUTICALS, Co., Ltd.
    Inventors: Shinichiro Nishimura, Risho Miyoshi, Kentaro Naruchi, Masakazu Tanaka, Masaharu Sato
  • Patent number: 10239951
    Abstract: Described herein are isolated bi-specific antigen binding constructs, e.g., antibodies. The bi-specific antigen binding constructs include two antigen binding polypeptide constructs, e.g., a Fab and an scFv. The first antigen-binding polypeptide construct monovalently and specifically binds to extracellular domain 4 (ECD4) of HER2 (human epidermal growth factor receptor 2); the second antigen-binding polypeptide construct monovalently and specifically binds to an extracellular domain (ECD) of HER3 (human epidermal growth factor receptor 3). One antigen binding polypeptide construct is a Fab format and the other antigen binding polypeptide construct is an scFv format. The bi-specific antigen binding constructs includes an Fc having two Fc polypeptides each having a CH3 domain for dimerization. Each Fc polypeptide is linked to the C-terminus of one of the antigen binding polypeptide constructs with or without a linker.
    Type: Grant
    Filed: May 8, 2014
    Date of Patent: March 26, 2019
    Assignee: Zymeworks Inc.
    Inventors: Gordon Yiu Kon Ng, Peter Wing Yiu Chan, Grant Raymond Wickman
  • Patent number: 10239952
    Abstract: Disclosed herein is a bi-specific form of a T cell receptor mimic (TCRm) mAb with reactivity to human immune effector cell antigen and a WT1 peptide/HLA-A epitope. This antibody selectively bound to leukemias and solid tumor cells expressing WT1 and HLA-A as well as activated resting human T cells to release interferon-(IFN-?) and to kill the target cancer cells in vitro. Importantly, the antibody mediated autologous T cell proliferation and directed potent cytotoxicity against fresh ovarian cancer cells. Therapeutic activity in vivo of the antibody was demonstrated in NOD SCID SCID Yc*(NSG) mice with three different human cancers expressing WT1/HLA-A2 including disseminated Ph+ acute lymphocytic leukemia (ALL), disseminated acute myeloid leukemia, and peritoneal mesothelioma. In both of the leukemia xenograft models, mice that received the antibody and T cells also showed longer survival and delayed limb paralysis.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: March 26, 2019
    Assignees: Memorial Sloan Kettering Cancer Center, Eureka Therapeutics, Inc.
    Inventors: David Scheinberg, Jingyi Xiang, Tao Dao, Su Yan, Cheng Liu
  • Patent number: 10239953
    Abstract: Disclosed herein is a bispecific inhibitor for use in treating thrombotic disorders, such as acute thrombotic disorders like stroke and thromboembolism. The bispecific inhibitor is based on monoclonal antibodies targeting TAFI and PAI-1, and shows efficacy in the presence or the absence of plasminogen activators such as tissue-type plasminogen activator (tPA).
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: March 26, 2019
    Assignees: KATHOLIEKE UNIVERSITEIT LEUVEN, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE CAEN BASSE NORMANDIE, CENTRE HOSPITALIER UNVIERSITAIRE DE CAEN
    Inventors: Paul Declerck, Simon De Meyer, Nick Geukens, Ann Gils, Marina Rubio, Denis Vivien, Tine Wyseure
  • Patent number: 10239954
    Abstract: The present disclosure relates to antibodies specific for urokinase-type plasminogen activator (uPA). According to certain embodiments, the anti-uPA antibody specifically binds to the active form of uPA. In certain aspects, the anti-uPA antibody that specifically binds to active uPA binds specifically to the active form of human uPA (e.g., the antibody does not cross-react with active forms of uPA from non-human organisms). In certain aspects, an anti-uPA antibody of the present disclosure competes for specific binding to uPA with plasminogen activator inhibitor type 1 (PAI-1), where binding of the antibody to uPA results in internalization of a complex that includes the antibody, uPA, and urokinase-type plasminogen activator receptor (uPAR). Also provided are antibodies that specifically bind to uPA and compete for binding to uPA with a synthetic ligand of uPA. The disclosure also provides anti-uPA antibody conjugates and compositions (e.g.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: March 26, 2019
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, CYTOMX THERAPEUTICS, INC.
    Inventors: Natalia Sevillano, Aaron M. Lebeau, Daniel Robert Hostetter, Charles S. Craik
  • Patent number: 10239955
    Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: March 26, 2019
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Shoichi Naito, Junji Onoda, Tasuku Tsukamoto, Katsutoshi Yamada, Shoji Yamane, Yoshito Numata, Kazuhiko Maekawa, Tatsuya Takahashi
  • Patent number: 10239956
    Abstract: The invention provides antibodies which bind to the ADP-ribosyl cyclase 2. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. The antibodies may be used for the treatment of human cancers, including acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer, ovarian cancer and pancreatic cancer and human inflammatory diseases, including asthma, gout, crohns, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, diabetes and atherosclerotic.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: March 26, 2019
    Assignee: Oxford BioTherapeutics Ltd
    Inventors: Christian Rohlff, Jonathan Alexander Terrett
  • Patent number: 10239957
    Abstract: Disclosed herein is a peptide containing conjugate comprising (P)c-(L)d-(G)e, wherein P is a peptide and each occurance of P is independently selected from Table 2; L is an optional linker and each occurance of L, if present, is independently selected from Table 3; G is a targeting ligand and each occurance of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. The conjugate can be administered to a subject either alone or in combination with a composition comprising R-(L)a-(G)b, wherein R is an oligonucleotide as defined herein, to inhibit expression of a gene of the subject.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: March 26, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Steven L. Colletti, Thomas J. Tucker, David M. Tellers, Boyoung Kim, Rob Burke, Kathleen B. Calati, Matthew G. Stanton, Rubina G. Parmar, Jeffery G. Aaronson, Weimin Wang
  • Patent number: 10239958
    Abstract: A process for modifying starch comprises atomising an aqueous slurry of non-pregelatinised starch into an internal chamber in a bi-fluid nozzle of a spray dryer and treating the atomized slurry, in the internal chamber, with superheated steam to cause partial gelatinisation of the starch. The aqueous slurry containing partially gelatinised starch is discharged through an outlet in the internal chamber into a reactor where the droplets containing the partially gelatinised starch are subjected to further treatment with superheated steam, resulting in the completion of the gelatinisation of the starch in the reactor. Also disclosed is a bi-fluid nozzle for use in spray drying starch which comprises a nozzle body, a nozzle cap and an internal chamber located between the nozzle body and the nozzle cap.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: March 26, 2019
    Assignee: Cargill, Incorporated
    Inventors: Marc Berckmans, Jozef Victor Jean-Marie Coppin, Stephane Jules Jerome Debon
  • Patent number: 10239959
    Abstract: The invention concerns a process for the manufacture of an acylated polymer composition comprising amylose and/or amylopectin, comprising a pre-treatment step in the presence of an acid and a hydroxycarboxylic acid, subsequent acylation and, preferably, a post-treatment step with an acid. The products obtained are useful as additives in inks, varnishes, lacquers, coatings, thickeners, adhesives or binders.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: March 26, 2019
    Assignee: SOLVAY ACETOW GMBH
    Inventors: Jana Lubkoll, Armin Stein
  • Patent number: 10239960
    Abstract: Products and processes that are related to phosphonated polysaccharide compositions, including phosphonated polysaccharide gels, having a substituent degree of substitution with a lower limit of 0.02 and an upper limit of 3, and having a weight average molecular weight with an upper limit of 5,000,000 g/mole, as well as to oil field application or fracturing fluid compositions comprising such phosphonated polysaccharide compositions.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: March 26, 2019
    Assignee: Rhodia Operations
    Inventors: Laurianne Timbart, Gilda Lizarraga, Gary Woodward, Subramanian Kesavan, David James Wilson